Revelation Biosciences, Inc.
REVB
$1.24
-$0.02-1.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.12% | 0.09% | -4.49% | -2.67% | -1.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.74% | -3.44% | -14.92% | -8.62% | -7.87% |
| Operating Income | -13.74% | 3.44% | 14.92% | 8.62% | 7.87% |
| Income Before Tax | 40.73% | 47.61% | 46.78% | -60.79% | -12,400.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.73% | 47.61% | 46.78% | -60.79% | -12,400.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.73% | 47.61% | 46.78% | -60.79% | -12,400.83% |
| EBIT | -13.74% | 3.44% | 14.92% | 8.62% | 7.87% |
| EBITDA | -13.80% | 3.47% | 14.99% | 8.69% | 7.93% |
| EPS Basic | 71.82% | 25.14% | -- | -- | -- |
| Normalized Basic EPS | 80.92% | 37.62% | -- | -- | -- |
| EPS Diluted | 71.82% | 25.14% | -- | -- | -- |
| Normalized Diluted EPS | 80.92% | 37.62% | -- | -- | -- |
| Average Basic Shares Outstanding | 5,650.12% | 6,840.71% | -- | -- | -- |
| Average Diluted Shares Outstanding | 5,650.12% | 6,840.71% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |